• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALERE SAN DIEGO, INC. INRATIO2 PT MONITORING SYSTEM; PROTHROMBIN TIME TEST

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALERE SAN DIEGO, INC. INRATIO2 PT MONITORING SYSTEM; PROTHROMBIN TIME TEST Back to Search Results
Model Number 200432
Device Problem High Test Results (2457)
Patient Problem Myocardial Infarction (1969)
Event Date 07/19/2015
Event Type  Injury  
Manufacturer Narrative
Investigation is pending.
 
Event Description
On (b)(4) 2015, a phone call was received from the distributor and transferred to alere (b)(4).The caller alleged a variance between the inratio inr results, the laboratory inr result and a point of care (poc) inr result.On (b)(4) 2015, the patient tested on the inratio and obtained an inr of 3.8, which was reported to his physician.The therapeutic range was 2.0-3.0.The patient did not state that any changes were made to his warfarin dose after this result was obtained.On (b)(4) 2015, the patient tested on the inratio and obtained an inr of 3.3, which was reported to his physician.His physician decreased his warfarin from a daily dose of 5mg to 2.5 mg on (b)(4) 2015 and (b)(4) 2015.He was ordered to continue warfarin 2.5 mg on mondays and fridays and warfarin 5mg the rest of the week.On (b)(4) 2015, the patient suffered a "heart attack" and was taken, by ambulance, to the hospital where he suffered another heart attack.The laboratory inr was 1.2.Treatment included intravenous (iv) heparin.The patient was diagnosed with a heart blockage and underwent a stent placement.On (b)(4) 2015, the laboratory inr was 1.1 and iv heparin was continued.On (b)(4) 2015 the patient was discharged from the hospital and prescribed nitrostat as well as other medications (names and doses not provided).The patient was unable to confirm his inr before being discharged.On (b)(4) 2015, the distributor transferred a call from the patient to asd.The physician had suggested another correlation to be performed and a visiting nurse was sent to the patient's home to perform testing.The nurse performed two separate finger-sticks for testing.The inratio inr was 1.2, and the nurse's point of care (poc) inr was 1.1.The patient stated that he was still concerned about the difference in results.There was no additional information provided.
 
Manufacturer Narrative
Corrections: brand name: removed inratio pt/inr test strips (as the complaint device) and added the inratio2 pt monitoring system.(monitor): d4 model #: removed inratio pt/inr test strip and added the monitor model 200432.Lot#: removed inratio pt/inr test strip lot number and included serial number of monitor as above.Removed the monitor as a concomitant medical product and added the inratio pt/inr test strips.G5 510k#: removed the inratio pt/inr test strip 510k# k092987 and added k072727 to reflect the inratio2 pt monitoring system.Labeled for single use?: changed from "yes" to "no" since the monitor is not a single use device.Usage of device: changed from "unknown" to "reuse" since the monitor is not a single use device.Investigation/conclusion: the monitor associated with the complaint was returned for investigation.Since lot# 355401 was depleted, lot# 355402 was utilized for the investigation.Lot#355402 is identical to 355401 except for the outer packaging and labeling.Therapeutic and normal donor testing was performed on the returned monitor using 355402 retained strips.The testing history and manufacturing records for ots 355401 and 355402 were reviewed and the lots met release specifications.Impedance curve analysis was performed on the customer's reported inratio values of 1.2, 3.3, and 3.8.The impedance curves associated with inratio values of 1.2 and 3.3 appeared normal in shape, while the impedance curve associated with inratio value of 3.8 was associated with an abnormal slope change.Our capa investigation (capa-(b)(4)) has determined that impedance curves with abnormal slope change can cause discrepant results.Further investigation has been performed under capa-(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INRATIO2 PT MONITORING SYSTEM
Type of Device
PROTHROMBIN TIME TEST
Manufacturer (Section D)
ALERE SAN DIEGO, INC.
9975 summers ridge road
san diego CA 92121
Manufacturer (Section G)
ALERE SAN DIEGO, INC.
9975 summers ridge road
san diego CA 92121
Manufacturer Contact
ya-ling king
9975 summers ridge road
san diego, CA 92121
8588052084
MDR Report Key5014899
MDR Text Key23515744
Report Number2027969-2015-00600
Device Sequence Number1
Product Code GJS
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K072727
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,distributor
Reporter Occupation Patient
Remedial Action Recall
Report Date 07/28/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Model Number200432
Device Lot Number355401
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer08/14/2015
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received08/19/2015
Was Device Evaluated by Manufacturer? Yes
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Removal/Correction NumberZ-0880, 0881, 0882-2015
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
-
-